Our vision is to advance the frontiers of science to provide better cancer care.
Our mission:
To produce cancer treatments and imaging products that do not interfere with the patients’ quality of life, and to advance the science of providing better cancer care.
Contact Us
Our mission:
To produce cancer treatments and imaging products that do not interfere with the patients’ quality of life, and to advance the science of providing better cancer care.
Contact Us
Our mission:
To produce cancer treatments and imaging products that do not interfere with the patients’ quality of life, and to advance the science of providing better cancer care.
Contact Us
Innovations in Cancer Pharmacology
DAROU was founded on the basic breakthrough discovery that cell surface regulators of iron dyshomeostasis (expressed exclusively on Pt resistance ovarian tumors) can be exploited for imaging and destruction of Pt resistant tumor cells. We have successfully leveraged this invention into an imaging and drug delivery engine, and produced robust data supporting the efficacy of these probes.
All of our precision detection and targeting probes are backed by 25 years of research in the gynecological cancer field.
Our Products Pipeline
In vivo Cancer Detection Probes
ADR6N1 Series
- These probes recognize and dock to the surface of platinum (Pt) resistant ovarian tumor cells and release detection agents such as fluorescent dyes, radioisotopes, heavy metals, and ultrasound bubbles, suitable for most currently available imaging instruments.
- Amenable to local and systemic administration.
In vivo Cancer Targeting Probes
ADR6P1 Series
- These probes dock to tumor surface receptors and release anticancer agents, including small molecules, peptides, antibodies, oligonucleotides.
- Amenable to local and systemic administration.
Blood Chemoresponse Assay Kits
ORP25 and ORP125
- These antibody array kits enrich, detect, and monitor biomarkers secreted by Pt-resistant ovarian tumors.
Who We Are
DAROU was founded by Roohangiz Safaei, Ph.D. Dr. Safaei specializes in the molecular biology of drug resistance, and has made extensive contributions to the field of Pt drug resistance in ovarian cancer. She has collaborated extensively with academics and pharmaceutical leaders in developing treatments for Pt resistant tumors.